GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Gabapentin - GRALISE

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Gralise / gabapentin extended-release

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Gabapentin formulations have different renal rules

Immediate-release gabapentin, GRALISE and HORIZANT are not interchangeable renal protocols. HORIZANT also has indication-specific schedules.

Before applying: Select the actual formulation and indication before using a dose or dialysis instruction.

GRALISE: exactly 60 appears in two source rows

The retrieved table prints both >=60 and 30-60, and GRALISE is not interchangeable with immediate-release gabapentin. This is a source-boundary issue, not a reason to average doses.

Before applying: Reconcile the exact value with the current product label and pharmacist review. Do not automatically assign a row or import another formulation's dialysis guidance.

Also check: Gabapentin formulations have different renal rules; GRALISE: exactly 60 appears in two source rows

Official source

GRALISE (gabapentin) tablets

Product / population
Adult PHN; formulation-specific once-daily product.
Renal measure
Not specified; verify before use
Titration and administration

With the evening meal: day 1, 300 mg; day 2, 600 mg; days 3-6, 900 mg; days 7-10, 1200 mg; days 11-14, 1500 mg; day 15, 1800 mg. Swallow whole. Reduce or stop gradually over at least one week.

Renal table

Cockcroft-Gault CrCl >=60 mL/min: 1800 mg once daily. The printed 30-60 band allows 600-1800 mg once daily, individualized; start at 300 mg and follow titration. Below 30 or on HD: do not administer. The table overlaps at exactly 60; confirm individual selection.

Source revision: 06/2026 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=466273b1-c9fc-3930-c94b-aa11394d5140

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Gralise

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

GRALISE only, with evening meal. Not immediate-release gabapentin or HORIZANT.

Renal method: CrCl by Cockcroft-Gault in stable renal function, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Gralise (gabapentin tablets)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

GRALISE gastroretentive tablets for adult postherpetic neuralgia; not interchangeable with other gabapentin products.

Renal method: Creatinine clearance (mL/min).
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

ambiguous source boundary

GRALISE: exactly 60 appears in two source rows

The retrieved table prints both >=60 and 30-60, and GRALISE is not interchangeable with immediate-release gabapentin. This is a source-boundary issue, not a reason to average doses.

How to use this: Reconcile the exact value with the current product label and pharmacist review. Do not automatically assign a row or import another formulation's dialysis guidance.

GlobalRPh RX List - Gralise (gabapentin tablets)Gabapentin immediate-release (Neurontin)Gabapentin enacarbil extended-release (Horizant)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGRALISE (gabapentin) tabletsGlobalRPh RX List - GraliseGlobalRPh RX List - Gralise (gabapentin tablets)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=466273b1-c9fc-3930-c94b-aa11394d5140

Product and population scope

Adult postherpetic neuralgia; GRALISE formulation only. Not interchangeable with immediate-release gabapentin or HORIZANT.

gabapentin-gralise:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

GRALISE (gabapentin) tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adult PHN; formulation-specific once-daily product.

Renal method: Not specified in this summary.
Source date: 06/2026
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Titration and administration

With the evening meal: day 1, 300 mg; day 2, 600 mg; days 3-6, 900 mg; days 7-10, 1200 mg; days 11-14, 1500 mg; day 15, 1800 mg. Swallow whole. Reduce or stop gradually over at least one week.

gabapentin-gralise:dm-466273b1-c9fc-3930-c94b-aa11394d5140-1 · Source locator: 2.1, Table 1

Renal table

Cockcroft-Gault CrCl >=60 mL/min: 1800 mg once daily. The printed 30-60 band allows 600-1800 mg once daily, individualized; start at 300 mg and follow titration. Below 30 or on HD: do not administer. The table overlaps at exactly 60; confirm individual selection.

gabapentin-gralise:dm-466273b1-c9fc-3930-c94b-aa11394d5140-2 · Source locator: 2.2, Table 2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=466273b1-c9fc-3930-c94b-aa11394d5140
Retrieved
2026-09-05
Exact label title
GRALISE (gabapentin) tablets
DailyMed Set ID
466273b1-c9fc-3930-c94b-aa11394d5140
Labeler
Almatica Pharma LLC
DailyMed page updated
2026-06-30
Label revision
06/2026
FDA application
New Drug Application
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
727e5aed8cccf3985fe50ccdd7df0ac5fb60c9a7c1045a5b0ddc24d5001d5bb5
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Gralise

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · GRALISE only, with evening meal. Not immediate-release gabapentin or HORIZANT.

Renal method: CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date: Revised April 2025
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Table 2 lists 1,800 mg once daily at CrCl at least 60, and 600 to 1,800 mg once daily at CrCl 30 to 60. Take with the evening meal. Individualize and titrate, starting at 300 mg; the complete titration schedule is in Table 1 and is not replaced by the maintenance range. GRALISE should not be administered below CrCl 30 or during hemodialysis. The published bands overlap at 60; both include the same upper maintenance dose, but the full source and patient tolerance still control.

RDM33-rxlist-gabapentin-gralise-C1 · Source locator: Dosage: renal impairment, Table 2.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/gralise-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date/version
Revised April 2025
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
448436039b63fbc448110258684f3b70b91150e14b0c6d111281798023dbfacf
Rxlist

GlobalRPh RX List - Gralise (gabapentin tablets)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · GRALISE gastroretentive tablets for adult postherpetic neuralgia; not interchangeable with other gabapentin products.

Renal method: Creatinine clearance (mL/min).
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The printed renal table lists 1800 mg once daily at CrCl >=60 and 600-1800 mg once daily at CrCl 30-60, individualized to response and tolerability. Exactly 60 appears in both rows; that overlap is retained for clarification, not automatically resolved. Do not administer GRALISE below CrCl 30 or in hemodialysis. Give with the evening meal and swallow tablets whole. Its titration and absorption differ from immediate-release gabapentin and HORIZANT; do not transfer their dose frequencies or dialysis supplements to this formulation.

RDM39-rxlist-gabapentin-gralise-41f39a5836-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/gralise-drug/
Retrieved
2026-09-07
Renal-function method
Creatinine clearance (mL/min).
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
041d522496e57630a55ee02e90fb4eedf7d08e9e7628e86619d8db2f1fcc7271

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=466273b1-c9fc-3930-c94b-aa11394d5140
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
official formulation addition
Local text SHA-256
fb7147ed689e516ad31839ff5571112d4647806dabbcff459e8ee4522fcff3a2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report